A Phase 1, Dose Escalation Study Of Pf-06664178 In Patients With Locally Advanced Or Metastatic Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 21 Feb 2018
Price : $35 *
At a glance
- Drugs PF 6664178 (Primary)
- Indications Breast cancer; Male breast cancer; Non-small cell lung cancer; Ovarian cancer; Solid tumours
- Focus Adverse reactions
- Sponsors Pfizer
- 31 Aug 2018 Biomarkers information updated
- 15 Jan 2018 Results assessing maximum tolerated dose and recommended phase 2 dose, published in the Investigational New Drugs.
- 08 Aug 2016 Status changed from active, no longer recruiting to discontinued.